IP Library Granted Patent US 8,872,124
Granted Patent B2
US 8,872,124 · App. 13/800,248 · Granted Oct 28, 2014

Systems and methods for assaying an eluate for technetium and molybdenum content

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,872,124
App. No.
13/800,248
Granted
Oct 28, 2014
Kind
B2
Abstract

A system for assaying an eluate for Technetium-99m and Molybdenum-99 content includes an inner ionization chamber including a well configured to receive the eluate, an outer ionization chamber concentric with the inner ionization chamber, and attenuating material positioned between the inner and outer ionization chambers. A computing device is configured to determine a Technetium-99m content of the eluate based on a first current measured in the inner ionization chamber, and determine a Molybdenum-99 content of the eluate based on at least a second current measured in the outer ionization chamber.

Claims (40)

1. A system for assaying an eluate for Technetium-99m and Molybdenum-99 content, the system comprising:

an inner ionization chamber including a well configured to receive the eluate;

an outer ionization chamber concentric with the inner ionization chamber;

attenuating material positioned between the inner and outer ionization chambers;

a computing device configured to:

determine a Technetium-99m content of the eluate based on a first current measured in the inner ionization chamber; and

determine a Molybdenum-99 content of the eluate based on at least a second current measured in the outer ionization chamber.

2. The system of claim 1 , wherein the outer ionization chamber is a high pressure Xenon gas chamber.

3. The system of claim 1 , wherein the attenuating material is made of at least one of tungsten and lead.

4. The system of claim 1 , wherein the system is configured to determine the Technetium-99m content and the Molybdenum-99 content of the eluate simultaneously.

5. The system of claim 1 , further comprising:

a first current measurement device communicatively coupled to the computing device and configured to measure the first current in the inner ionization chamber; and

a second current measurement device coupled to the computing device and configured to measure the second current in the outer ionization chamber.

6. The system of claim 5 , wherein the first and second current measurement devices are source measurement units (SMUs).

7. The system of claim 1 , wherein the computing device is further configured to:

calculate a portion of the determined Molybdenum-99 content attributable to 322.41 keV energy from decay of Technetium-99m; and

subtract the calculated portion from the determined Molybdenum-99 content to generate a corrected Molybdenum-99 content.

8. The system of claim 1 , wherein the inner and outer ionization chambers are annular.

9. A method for assaying an eluate for Technetium-99m and Molybdenum-99 content, the method comprising:

placing the eluate in a well of an inner ionization chamber;

measuring a first current in the inner ionization chamber;

measuring a second current in an outer ionization chamber, wherein the outer ionization chamber is concentric with the inner ionization chamber and separated from the inner ionization chamber by attenuating material;

determining, using a computing device, a Technetium-99m content of the eluate from the first measured current; and

determining, using the computing device, a Molybdenum-99 content of the eluate from at least the second measured current.

10. The method of claim 9 , wherein measuring a second current in an outer ionization chamber comprises measuring a second current in a high pressure Xenon gas chamber.

11. The method of claim 9 , further comprising calculating, using the computing device, a ratio of Technetium-99m to Molybdenum-99 in the eluate.

12. The method of claim 9 , wherein the Technetium-99m content and the Molybdenum-99 content of the eluate are determined simultaneously.

13. The method of claim 9 , wherein measuring a first current comprises measuring the first current using a first source measurement unit, and wherein measuring a second current comprises measuring the second current using a second source measurement unit.

14. The method of claim 9 , further comprising:

calculating, using the computing device, a portion of the determined Molybdenum-99 content attributable to 322.41 keV energy from decay of Technetium-99m; and

subtracting, using the computing device, the calculated portion from the determined Molybdenum-99 content to generate a corrected Molybdenum-99 content.

15. A radiation detection device for detecting a plurality of radioactive isotopes in an eluate, the radiation detection device comprising:

an inner ionization chamber including a well that receives the eluate, wherein a first current is generated in the inner ionization chamber in response to a first radioactive isotope present in the eluate;

an outer ionization chamber concentric with the inner ionization chamber, wherein a second current is generated in the outer ionization chamber in response to a second radioactive isotope present in the eluate; and

attenuating material positioned between the inner and outer ionization chambers.

16. The radiation detection device of claim 15 , wherein the first radioactive isotope is Technetium-99m and the second radioactive isotope is Molybdenum-99.

17. The radiation detection device of claim 15 , wherein the outer ionization chamber is a high pressure Xenon gas chamber.

18. The radiation detection device of claim 15 , wherein the attenuating material is made of at least one of tungsten and lead.

19. The radiation detection device of claim 15 , wherein the attenuating material has a thickness of approximately 0.25 inches.

20. The radiation detection device of claim 15 , wherein the inner and outer ionization chambers are annular.

Assignments (6)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
CHANGE OF NAME Recorded Apr 3, 2023
From: MALLINCKRODT NUCLEAR MEDICINE LLC
To: CURIUM US LLC
Reel/Frame 063240/0591 →
RELEASE OF SECURITY INTEREST Recorded Jan 31, 2017
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: MALLINCKRODT NUCLEAR MEDICINE LLC
Reel/Frame 041131/0213 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2016
From: MALLINCKRODT LLC
To: MALLINCKRODT NUCLEAR MEDICINE LLC
Reel/Frame 039149/0234 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2013
From: GRAVES, KEVIN B.; PETROFSKY, BRYAN S.; VERMA, SUMIT
To: MALLINCKRODT LLC
Reel/Frame 031479/0689 →